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Purpose. Polyphenol metabolites are key mediators of the biological activities of 44 
polyphenols. This study aimed to evaluate the long-term effects of a high-fat high-45 
sucrose (HFHS) diet on the metabolism of proanthocyanidins (PAs) from grape seed 46 
extract (GSE).   47 
Methods. Adult female Wistar Kyoto rats were fed a standard (STD) or HFHS diet 48 
supplemented or not with GSE for 16 weeks. PA metabolites were determined by 49 
targeted HPLC-MS/MS analysis.  50 
Results. A lower concentration of total microbial-derived PA metabolites was present in 51 
urine and the aqueous fraction of faeces in the HFHS + GSE group than in the STD + 52 
GSE group. In contrast, a tendency towards the formation of conjugated (epi)catechin 53 
metabolites in the HFHS + GSE group was observed.  54 
Conclusions. These results show that a HFHS diet significantly modifies PA 55 
metabolism, probably via: i) a shift in microbial communities not counteracted by the 56 
polyphenols themselves; and ii) an up-regulation of hepatic enzymes.  57 










1. Introduction 65 
Metabolic syndrome (MetS) is a cluster of risk factors (abdominal obesity, 66 
hypertension, hyperglycaemia, hypertriglyceridaemia) that increases the risk of 67 
developing type 2 diabetes or cardiovascular diseases [1]. MetS is increasingly 68 
becoming a public health problem, affecting some 20%-30% of the population in 69 
developed countries [2]. MetS has been shown to result from factors that are common in 70 
current Western lifestyles: sedentariness and unhealthy dietary patterns including an 71 
excess of fat and simple carbohydrates, i.e., high-fat high-sucrose (HFHS) diets. The 72 
metabolic alterations caused by a HFHS dietary pattern have been thoroughly studied in 73 
animal models, showing that it triggers insulin resistance, hyperinsulinaemia, 74 
hyperlipidaemia, elevated blood pressure, hepatic steatosis and both endothelial-75 
dependent and endothelial-independent arterial dysfunction, among other effects [3-5]. 76 
HFHS diets have been used in several animal models to evaluate the potential role of 77 
different bioactive food compounds in the modulation of MetS; for instance, a HFHS 78 
diet has been supplemented with ω-3 polyunsaturated fatty acids of marine origin [6], 79 
the iminosugar D-fagomine [7] or with polyphenols [8]. 80 
Proanthocyanidins (PAs) constitute a class of polyphenols; a broad group of dietary 81 
phytochemicals. The members of this class range from dimers to high-molecular-weight 82 
polymers of different constituent flavanol units and are notably present in certain 83 
foodstuffs such as cocoa, grapes and nuts [9]. In recent years, several studies in animal 84 
models have shown that PAs may play a beneficial role in modulating MetS through a 85 
combination of mechanisms, i.e., direct inhibition of enzymes involved in the 86 
metabolism of carbohydrates, improvement in insulin sensitivity, repression of intestinal 87 
lipid absorption, activation of endogenous antioxidant systems and reduction of the 88 




polyphenols is their metabolic fate since, once ingested, they are extensively 90 
transformed by phase I and phase II enzymes, as well as by the gut microbiota; PA-91 
derived metabolites may ultimately be responsible for the biological effects of PAs [15-92 
16]. Other components present in the diet, e.g., milk or oil, may affect the 93 
bioavailability of polyphenols [17-18]. Other physiological aspects, such as age, do not 94 
seem to play a relevant role in the metabolism of PAs [19]. Therefore, to properly 95 
ascertain the role of supplemented polyphenols, the effect of the overall diet on the 96 
profile and amount of potentially active circulating metabolites must be evaluated. 97 
Several studies in animal models have supplemented HFHS diets with different 98 
polyphenols in order to determine how they modulate MetS [20-22]. However, the 99 
levels of polyphenol-derived metabolites after a HFHS diet were not assessed. Also, the 100 
effect of combined supplementation with polyphenols and a probiotic on circulating 101 
phenolic metabolites was evaluated in animals fed a HFHS diet [23], but no comparison 102 
was provided of the effects of this supplementation on animals fed a standard (STD) 103 
diet. 104 
 Therefore, the aim of this study was to compare the levels of metabolites derived from 105 
grape PAs in rats fed a HFHS diet with those in rats fed a STD diet; which may provide 106 
useful information for understanding the reported effects of the addition of polyphenols 107 
to HFHS diets.  108 
2. Materials and methods 109 
2.1 Chemicals and reagents  110 
The STD diet, Global 2014, and HFHS diet, TD 08811, were from Teklad Global 2014 111 
(Harlan Teklad Inc., Indianapolis, IN, USA). Fine Grajfnol
®
 powder 98% (grape seed 112 




According to the manufacturer, this extract contained 95% PAs (UV) of which 60% was 114 
B2 procyanidin dimer (HPLC), with a mean degree of polymerization of 2. So the 115 
extract contained mainly dimmers, with some amounts of monomers and trimers. Ash 116 
content was  1.5% and loss on drying was  5.0%. Porcine gelatin type A 240/260 was 117 
from Juncà (Girona, Spain) and soybean lecithin Topcithin 50 from Cargill (Barcelona, 118 
Spain). Organic unrefined soybean oil (first cold pressing) was from Clearspring Ltd. 119 
(London, UK).   120 
Ketamine chlorhydrate was purchased from Merial Laboratorios (Barcelona, Spain) and 121 
xylacine from Química Farmacéutica (Barcelona, Spain). Standards of (−)-(epi)catechin 122 
(EC) (≥ 98%), (−)-(epi)gallocatechin (EGC) (≥ 95%), 3-hydroxyphenylacetic acid (≥ 123 
99%), 4-hydroxyphenylacetic acid (≥ 98%), 3,4-dihydroxyphenylacetic acid (≥ 98%), 3- 124 
hydroxybenzoic acid (≥ 99%), 4-hydroxybenzoic acid (≥ 99%), homovanillic acid (≥ 125 
98%), vanillic acid (≥ 97%), caffeic acid (≥ 98%), 3,4-dihydroxyphenylpropionic acid 126 
(≥ 98%), 3-(4-hydroxyphenyl)propionic acid (≥ 98%), 3,4-dihydroxybenzoic acid (≥ 127 
97%), benzoic acid (≥ 99%), hippuric acid (≥ 98%), ferulic acid (≥ 99%), isoferulic acid 128 
(≥ 97%), p-coumaric acid (≥ 98%), m-coumaric acid (≥ 98%), gallic acid (≥ 97%), 129 
enterodiol (≥ 95%), phenylacetic acid (≥ 99%), taxifolin (≥ 85%), and tert-130 
butylhydroquinone and formic acid (analytical grade) were obtained from Sigma 131 
Chemical (St Louis, MO, USA). Methanol (analytical grade) and hydrochloric acid (≥ 132 
85%) were from Panreac (Castellar del Vallès, Spain). Acetonitrile (HPLC grade) was 133 
obtained from Merck (Darmstadt, Germany). Water for the assay solutions was obtained 134 
using a Milli-Q water purification system (Millipore Corporation, Billerica, MA, USA). 135 
2.2 Animals   136 
A total of twenty female Wistar Kyoto (WKY) rats (Janvier, Le Genest-St-Isle, France), 137 




22ºC ± 2ºC and a relative humidity of 50% ± 10%. All the procedures adhered strictly to 139 
the European Union guidelines for the care and management of laboratory animals, and 140 
were approved by the CSIC Bioethical Issues Subcommittee (ref. AGL2009-12 374-141 
C03-03). Thus they were performed in accordance with the ethical standards laid down 142 
in the 1964 Declaration of Helsinki and its later amendments. 143 
2.3 Experimental design  144 
The rats were randomly divided into four groups, each (n = 5) fed a different diet: 145 
control (STD diet); HFHS diet; STD diet supplemented with GSE (STD + GSE); HFHS 146 
diet supplemented with GSE (HFHS + GSE). The animals were given access to feed 147 
and water ad libitum. The composition of each diet is provided in Table 1. 148 
The diets were prepared in-house and pelletized by lyophilization. To prevent oxidation 149 
and contamination by fungi, the dry pellets were vacuum packed and stored at 4ºC until 150 
used. To guarantee the proper mixture of the different components and an adequate 151 
consistency of the final pellet, soybean lecithin and porcine gelatin were added. tert-152 
Butylhydroxiquinone was added as an antioxidant.  153 
The animals received water and the pelleted feed for 18 weeks after being randomly 154 
assigned to the four dietary groups. Between weeks 14 and 16 of the experiment, the 155 
rats were placed in metabolic cages for urine and faeces collection, and deprived of food 156 
for 24 h.  157 
2.4 Sample processing  158 
The biological samples were prepared according to previously described procedures for 159 
the extraction of phenolic metabolites [24-26]. On collection, urine samples were 160 
acidified with HCl (1 mM, 5 μL) then urine and faeces were frozen in liquid nitrogen 161 




suspended in 1 mL of acid water (water acidified to pH 3 with formic acid). Then, 163 
taxifolin (100 μL of a 50 ppm solution) was added to each sample as an internal 164 
standard, to obtain a final concentration of 5 ppm. The samples were then subjected to 165 
solid-phase extraction in Oasis HLB (60 mg) cartridges from Waters Corporation 166 
(Mildford, MA, USA). The cartridges were activated with methanol (1 mL) and acid 167 
water (2 mL) and the samples loaded. To remove interfering components, the samples 168 
were washed with acid water (9 mL) and then the phenolic compounds were eluted with 169 
methanol (1 mL). The eluate was evaporated under nitrogen and the residue 170 
reconstituted with 500 μL of the initial HPLC mobile phase ([A], see below). The 171 
temperature of evaporation was kept under 37ºC to avoid deterioration of the phenolic 172 
compounds. The samples were filtered through a polytetrafluoroethylene 0.45 μm 173 
membrane from Waters Corp. into amber vials for HPLC-MS/MS analysis. 174 
Faeces samples were re-suspended in acid water (1:1 w/w) and homogenized using a 175 
vortex. Then, after adding the internal standard (taxifolin, 5 ppm) the mixtures were 176 
centrifuged (10000 g, 10 min at 4ºC), and the supernatant was freeze dried and re-177 
suspended in 1 mL of acid water and homogenized using a vortex, and later subjected to 178 
SPE and the workup process as described for the urine samples. 179 
2.5 HPLC-ESI-MS/MS analysis of polyphenol metabolites 180 
An Applied Biosystems (PE Sciex, Concord, Ontario, Canada) API 3000 triple 181 
quadrupole mass spectrometer with a TurboIon spray source was used in negative mode 182 
to obtain MS and MS/MS data, according to procedures described previously [24-26]. 183 
Liquid chromatography separations were performed using an Agilent 1100 series liquid 184 
chromatograph system (Agilent, Waldbronn, Germany) equipped with a Phenomenex 185 




Phenomenex Securityguard C18 (4 x 2.0 mm i.d.) column. Gradient elution was 187 
performed with a binary system consisting of: [A] 0.1% aqueous formic acid and [B] 188 
0.1% formic acid in CH3CN. An increasing linear gradient (v/v) of [B] was used, 189 
[t(min), % B]: 0,8; 10,23; 15,50; 20,50; 21,100; followed by a re-equilibration step. 190 
Each metabolite in the urine samples was first identified by multiple reaction 191 
monitoring (MRM) of the transitions of the putative metabolites using a dwell time of 192 
100 ms and then confirmed either by comparison with a standard when available, repeat 193 
MRM with a second characteristic transition and posterior comparison of the results 194 
with the retention time obtained in the first MRM, or neutral-loss and product ion scan 195 
experiments. The cycle time used was 2 s. The list of metabolites to be searched for was 196 
compiled from the literature on the bioavailability of grape polyphenols [24-27]. 197 
Analyst 1.4.2 software from AB Sciex was used for data acquisition and processing. 198 
Calibration curves for each metabolite were plotted using between 4 and 11 standards at 199 
different concentrations (ranging from 0.001 to 60 ppm). The concentrations obtained 200 
from the calibration curves were further corrected by the internal standard. When no 201 
commercial standard was available, the metabolites were quantified using a structurally 202 
related compound. The standard may still show a different response from that of the 203 
metabolite, so this method cannot be considered to provide proper quantification and 204 
should therefore be used mainly for comparative purposes. Details of the MRM 205 
transitions used, the conditions of the MS experiments, the standards used and the 206 
strategy employed for the identification of each metabolite (comparison with 207 
commercial standard or analysis of MS/MS fragmentation pattern) are provided in 208 
Table S1. 209 




Results are expressed as mean concentrations (µM) with standard error of the mean 211 
(SEM). Also, to facilitate comparisons between groups, the values corresponding to the 212 
HFHS, STD + GSE and HFHS + GSE groups were divided by those of the STD group, 213 
to obtain the relative incremental factor or x-fold increase. The non-parametric Kruskal-214 
Wallis and Mann-Whitney U tests were applied to analyse significant differences (P < 215 
0.05) between groups. The Kruskal-Wallis test was applied to determine any significant 216 
difference between the treatments and, if any were detected, the Mann-Whitney U test 217 
was used to compare all the different pairs of the treatments. The SPSS IBM 19 package 218 
for Windows was used throughout. 219 
3. Results 220 
3.1 Microbial-derived metabolites in urine 221 
Forty-eight transitions, corresponding to microbial metabolites reported to be formed 222 
during the intestinal fermentation of PAs (25) were searched for in the samples. Table 2 223 
shows the concentration data for the metabolites detected, as well as the x-fold 224 
incremental factors compared to the STD group.  225 
As expected, in most cases the metabolite concentrations in the STD + GSE group were 226 
significantly higher than in the STD control and HFHS groups. Meanwhile, the 227 
concentrations of PA metabolites when the high-dense-energy diet was supplemented 228 
with GSE (HFHS + GSE group) were significantly lower than those recorded for the 229 
STD + GSE group. This was observed for metabolites belonging to all the steps along 230 
the PA fermentation pathways (valerolactones, lignans, phenylvaleric acids, 231 
phenylpropionic acids, phenylacetic acids, benzoic acids, cinnamic acids and 232 
glyccinated benzoic acids), and was particularly marked for phenylvaleric acids and 233 




classes in the HFHS + GSE group were seven-fold and nearly twenty-fold lower, 235 
respectively, than in the STD + GSE group.  236 
 3.2 Microbial-derived metabolites in faeces 237 
Ten microbial-derived metabolites were identified in faeces; Table 3 shows the 238 
concentration data of the metabolites and the x-fold incremental factors compared to the 239 
STD diet. The same tendencies as observed for microbial-derived metabolites in urine 240 
were found in faeces: a) there was a significant increase in the overall concentration of 241 
these compounds in the STD + GSE group, compared to the non-supplemented groups; 242 
b) the formation of microbial-derived metabolites was lower in the HFHS + GSE group. 243 
Thus, for most of the compounds detected, the concentrations in the HFHS + GSE 244 
group were significantly lower than in the STD + GSE group.  245 
3.3 Conjugated metabolites of (epi)catechin and (epi)gallocatechin in urine 246 
A total of 39 transitions were searched for in urine, corresponding to monoconjugated, 247 
diconjugated and triconjugated (derived from the combination of methylated or Me, 248 
sulfated or Sulf and glucuronidated or Gluc forms) metabolites of EC and EGC. Among 249 
them, 15 metabolites were detected in the samples: 5 monoconjugated (EC 250 
glucuronidated in different positions), 7 diconjugated (five of EC and two of EGC) and 251 
three triconjugated (two of EC and one of EGC) (Table 4). They were identified using 252 
further MRM or their MS/MS fragmentation patterns (Table S1).  253 
Five EC monoglucuronides were detected; one exhibited its highest concentrations in 254 
the STD + GSE group, while three others were detected at their highest concentrations 255 
in the HFHS + GSE group. With regards to the diconjugated EC metabolites, a tendency 256 
towards significantly higher concentrations in the HFHS + GSE group than in the STD 257 
+ GSE group was observed. No significant difference was observed between the groups 258 




of conjugated metabolites in urine was significantly higher in the HFHS + GSE group 260 
than in the other three groups. 261 
4. Discussion   262 
In this study, we explored the effects of a HFHS diet on the metabolic fate of 263 
supplemented grape PAs, compared to a STD diet with or without this supplementation. 264 
Much effort has been devoted to properly characterizing the transformation of PAs after 265 
their intake, based on animal studies, in which they were fed a STD diet, or in human 266 
studies, involving either acute PA intake or a controlled and balanced diet [27]. 267 
However, since Western diets typically present an excess of fat and simple 268 
carbohydrates with respect to health recommendations, and it is known that other 269 
dietary components may affect the bioavailability of polyphenols, the potential effect of 270 
this dietary pattern on the transformation of polyphenols needs to be evaluated. 271 
Specifically, we determined here the levels of PA-derived metabolites after 272 
supplementing rats on a HFHS diet for a period of 16 weeks; representative of long-273 
term adherence to a high-energy-dense diet.  274 
Overall, the profiles of metabolites detected were similar to those previously reported in 275 
urine and faeces after supplementation with grape PAs [24-25], and they were within 276 
the same ranges as those reported in studies with similar supplementation over shorter 277 
periods [28]. Regarding the apparently paradoxical detection of valerolactones in the 278 
HFHS group which was fed a synthetic diet that did not contain polyphenols, it should 279 
be remarked that several studies in humans have found basal concentrations of these 280 
compounds after as long as 72 h of a polyphenol-free diet [26,29], despite the fact that  281 
their renal excretion takes place 8-24 h after intake [30-31]. This seems to indicate that, 282 
although PAs are the main precursors of valerolactones [26], a minor fraction of these 283 




Metabolome Database [32].  285 
The most remarkable effect we observed was that many microbial metabolites were 286 
significantly decreased in the HFHS-GSE group, as compared to the STD-GSE group, 287 
in both urine and the aqueous fraction of faeces- representative of those in contact with 288 
the intestinal epithelium [33]. Therefore, the high-energy-dense diet reduces the amount 289 
of polyphenol metabolites bioavailable and bioaccessible in the gut. Overall, this is 290 
probably due more to a decrease in their formation more than in their absorption, since 291 
the same tendency was observed in urine (post-absorption) that in faeces (not absorbed). 292 
Nevertheless, for some specific compounds, such as 4-hydroxyphenylpropionic acid, a 293 
decrease in their absorption should not be discarded, since the HFHS-GSE group 294 
showed the highest concentration values in the faeces. The present results may have 295 
implications for the potential beneficial effects of GSE supplementation when following 296 
a HFHS diet, since increasing evidence shows that the microbial metabolites of 297 
polyphenols play a key role in their health-related effects [16]. Along these lines, it was 298 
recently reported that 3,4-dihydroxybenzoic acid (one of the compounds whose 299 
circulation was found to be reduced when following the HFHS diet in this study) has the 300 
capacity to activate components within the insulin signalling pathway [34]. Similarly, 301 
the circulating levels of urolithin A glucuronide, a microbial metabolite of ellagitannins, 302 
another class of polyphenols, were inversely associated with impaired glycaemic control 303 
[35].  304 
Another important implication of the effects we observed in the microbial 305 
transformation of PAs when following a HFHS diet are the modifications to the 306 
microbiota responsible for that very transformation. We previously reported that a 307 
HFHS diet induces a shift in bacterial species towards a higher prevalence of 308 




[36]. Moreover, in both rodents and humans, a shift towards lower values of the ratio 310 
Bacteroidetes/Firmicutes, with a loss of diversity in rodents, has been related with a fat 311 
phenotype [37-38]; although this has not been convincingly confirmed and some 312 
authors report contradictory results in humans [39]. Information on the bacterial species 313 
involved in the transformation of polyphenols is still limited [40], as is overall 314 
knowledge of the two-way interaction polyphenols–gut microbiota [41]. However, it 315 
seems plausible that the modifications to the microbiota caused by a HFHS diet 316 
selectively affect species capable of transforming polyphenols. At the same time, 317 
polyphenols may be capable of modifying the composition of gut microbiota, as 318 
suggested by the increase in the population of Bifidobacterium and decrease in 319 
Enterobacteriales after the supplementation of healthy humans with PA-rich GSE [42]. 320 
Opposite effects on the same bacterial types have also been attributed to high-energy-321 
dense diets and obesity in rodents [43] and humans [44]. GSE might counteract a 322 
putative decrease in PA-processing bacteria caused by a HFHS diet, but our results 323 
suggest that this is not the case as the concentration of microbial-derived metabolites 324 
was lower in the HFHS + GSE group than in the STD + GSE group- nevertheless, it 325 
kept higher than in the HFHS group. Similarly, supplementation of a HFHS diet with 326 
resveratrol did not counteract the dysbiosis triggered by a HFHS diet; while, in contrast, 327 
quercetin supplementation did compensate for the diet-induced changes. These results 328 
suggest differential effects depending on the type of polyphenol [22]. Interestingly, 329 
when animals fed a HFHS diet received a combined supplementation with cranberry 330 
polyphenols and a probiotic, the latter  increased the circulation of phenolic metabolites 331 
[23]. 332 
Additionally, a tendency towards increased formation of conjugated EC metabolites in 333 




enzymes in enterocytes and liver. It has been reported that the activity of the liver 335 
cytochrome P450 2E1 is increased during non-alcoholic steatohepatitis [45]; a 336 
pathology linked to high-fat diets. It has also been reported that the hepatic expression 337 
of uridine 5’-diphosphate glucuronosyltransferase (the enzyme responsible for the 338 
glucuronidation of polyphenols) is up-regulated in male rats fed a HFHS diet, which is 339 
related, among other things, to increased expression of the proliferator-activated 340 
receptor α (PPARα), which appears when consuming such a diet [46]. Although those 341 
authors did not find the same effects in female rats, our results indirectly seem to 342 
indicate a similar up-regulation of this enzyme or those involved in the sulfation or 343 
methylation of EC after long-term exposure to a HFHS diet. Another possible 344 
explanation for the increase in EC conjugates would be delayed exposure to phase II 345 
enzymes associated with longer digestion times in animals fed a HFHS diet.   346 
The dose used in this study (30 mg PA/kg body weight of rat) would be equivalent to a 347 
daily dose of 4.9 mg/kg body weight in humans [47], i.e., 340 mg/d for a 70 kg adult. 348 
Since median daily polyphenol intake in humans is spread over a wide range, from 349 
about 150 to nearly 500 mg/p/day [48], significantly large subpopulations consume 350 
more polyphenols than the amount equivalent to the dose used in the present study. As 351 
no adverse effects have ever been reported, this dose could certainly be considered safe. 352 
Indeed, toxicological studies in rats report no adverse effect at doses much higher than 353 
that used in this study [49]. Similar doses of GSE have been shown to have beneficial 354 
effects on variables related to metabolic syndrome, such as lipidaemia—in rats and 355 
humans—or insulin metabolism—in rats [10,12]. 356 
This study has some limitations. First, a higher number of animals would have 357 
strengthened the statistical significance of the differences detected in some metabolites. 358 




does not invalidate our overall conclusions. Second, due to the limited number of 360 
commercial standards of PA metabolites that are currently available, the results had to 361 
be expressed as equivalents of other metabolites; thus, the values provided here should 362 
only be used for comparative purposes.  363 
In summary, a HFHS diet significantly decreased the production of microbial-derived 364 
PA metabolites in GSE-supplemented rats, with respect to PA metabolism in animals 365 
fed the STD diet. At the same time, an increase in conjugated EC metabolites was 366 
observed in the HFHS group; probably due to up-regulation of hepatic enzymes. Our 367 
results seem to indicate a shift in the microbial populations triggered by a HFHS diet 368 
that is not reversed by the polyphenols in GSE. This effect should be further studied- 369 
nevertheless, the concentrations of microbial-derived PA metabolites kept higher in the 370 
HFHS + GSE group than in the HFHS group. Since microbial metabolites seem to be 371 
key mediators of the biological activities of polyphenols, a decrease in their formation 372 
when following a HFHS diet would presumably affect the health-related properties of 373 
polyphenols.  374 
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Table 1. Composition of experimental diets  
 
 Diet 
STD HFHS STD-GSE HFHS-GSE 
Ingredients (g)     









   TBHQ  0.08 0.08 0.08 0.08 
   Porcine gelatin  25.0 25.0 25.0 25.0 
   Soybean lecithin 6.0 22.0 6.0 22.0 
   Soybean oil 17.4 22.0 17.4 22.0 
   Grajfnol
®3




   Protein (% by weight) 16.0 20.9 16.0 20.9 
   Carbohydrate (% by weight) 66.8 47.4 66.8 47.4 
   Fat (% by weight) 6.0 25.6 6.0 25.6 
   Energy from protein (%) 16.5 16.5 16.5 16.5 
   Energy from carbohydrate (%) 69.4 37.7 69.4 37.7 
   Energy from fat (%) 14.1 45.8 14.1 45.8 
   Total energy density (Kcal/g )
7
 3.9 5.1 3.9 5.1 
 
1 
Standard flour (Teklad Global 2014), containing wheat middlings, ground wheat, ground corn, corn 
gluten meal, calcium carbonate, soybean oil, dicalcium phosphate, iodized salt, L-lysine, vitamin E 
acetate, DL-methionine, magnesium oxide, choline chloride, manganous oxide, ferrous sulfate, 
menadione sodium bisulfite complex (source of vitamin K activity), zinc oxide, copper sulfate, niacin, 
calcium pantothenate, calcium iodate, pyridoxine hydrochloride, riboflavin, thiamin mononitrate, vitamin 
A acetate, vitamin B12 supplement, folic acid, cobalt carbonate, biotin and vitamin D3 supplement. 
2 
High-fat high-sucrose diet (Tekland TD 08811), containing sucrose, anhydrous milkfat, casein, 
maltodextrin, corn starch, cellulose, mineral mix AIN-93G-MX, soybean oil, vitamin mix AIN-93G-VX, 




dose was adjusteded to provide a daily proanthocyanidin dose of 30 mg/kg body weight (body 
weight was higher in rats following a HFHS diet). 
4
 Energy density is estimated as metabolizable energy based on the Atwater factors, assigning 4kcal/g to 
protein, 9kcal/g to fat, and 4kcal/g to carbohydrate, including dietary fiber. 




Table 2. Microbial-derived proanthocyanidin metabolites in urine from rats fed a standard (STD) diet or a high-fat high-sucrose (HFHS) diet 
without or with grape seed extract (GSE). Results expressed as µM, after quantification with structurally similar commercial standards (seeTable 
S1). 
Metabolite STD HFHS STD+ GSE HFHS + GSE 
 mean + s.e.m. mean + s.e.m. x-fold
1
 mean + s.e.m. x-fold
1
 mean + s.e.m. x-fold
1
 
Valerolactones          
  3- or 4-Hydroxyphenylvalerolactone 1.43 + 0.43 2.34 + 0.54 1.6 21.39 + 7.31
**&&
 15.0 0.94 + 0.52
$$
 0.6 





  Gluc-3,4-dihydroxyphenylvalerolactone 3.05 + 0.93 14.97 + 5.56 4.9 9.3 + 1.66
*
 3.0 8.72 + 3.04 2.9 
  Sulf-3,4-dihydroxyphenylvalerolactone 0.94 +0.58 n.d. - 77.49 + 6.63
**&&
 82.4 51.41 + 26.57
*$$
 54.5 
  3-Hydroxyphenylmethylvalerolactone 1.43 + 0.43 7.99 + 2.12 5.6 5.26 + 1.49
**
 3.7 5.00 + 2.48 3.5 
  4-Hydroxyphenylmethylvalerolactone 12.75 + 4.36 46.49 + 1.81 3.6 35.43 + 9.84 2.8 35.07 + 14.14 2.7 
  Gluc-3-hydroxymethylphenylvalerolactone 6.68 + 2.52 17.25 + 6.14 2.6 9.66 + 1.60 1.4 5.66 + 1.82 0.8 
  Sulf-3- ó 4-hydroxymethylphenylvalerolactone 4.12 + 1.37 21.11 + 9.35 5.1 5.17 + 0.93 1.3 18.55 + 4.61
*
 4.5 
  Total  30.66 + 6.43 116.12 + 34.87 3.6 175.93 + 25.19
**
 5.7 126.43 + 46.58 4.2 
Lignans        
  Enterolactone
2
 > 60 > 60  > 60  > 60  
Phenylvaleric acids        
  3-Hydroxyphenylvaleric acid  1.84 + 0.80 n.d.
**
 - 5.76 + 0.87
*&&
 3.1 3.06 + 1.22
$$
 1.7 
  4-Hydroxyphenylvaleric acid  0.27 + 0.10 0.40 + 0.10 1.5 2.67 + 0.90
**&&
 10.0 2.06 + 0.69
*&
 7.5 
  3,4-Dihydroxyphenylvaleric acid 0.52 + 0.15 6.14 + 1.83 11.8 2.66 + 0.69
*
 5.1 4.18 + 1.30 8.1 




 35.8 1.01 + 0.50
$$
 0.6 




 16.4 10.30 + 3.44
$$
 2.4 
Phenylpropionic acids        






 2.0 24.13 + 8.71
$$
 0.06 
  Gluc-3-  or-  4hydroxyphenylpropionic acid 1.27 + 0.77 24.31 + 9.33 19.2 0.96 + 0.12 0.8 15.31 + 6.51
*$$
 12.1 
Dihydrocaffeic acid (3,4-  
Dihydroxyphenylpropionic acid)  0.22 + 0.10 0.67 + 0.24 3.1 3.21 + 2.59
*
 14.8 0.32 + 0.17 1.5 








 2.1 42.63 + 15.65
$$
 0.1 
Phenylacetic acids         
  3-Hydroxyphenylacetic acid 3.74 + 1.40 4.71 + 1.57 1.3 24.10 + 3.79
**&&
 6.4 7.23 + 3.11
$
 1.9 




 28.3 37.99 + 17.26
$
 10.5 
  3,4-Dihydroxyphenylacetic acid 0.05 + 0.02 0.56 + 0.22 10.9 0.58 + 0.28
**
 11.6 0.35 + 0.16 6.8 
  Sulf-3,4-dihydroxyphenylacetic acid 0.46 + 0.26 0.76 + 0.30 1.6 0.47 + 0.11 1.0 0.53 + 0.18 1.1 
  Total   7.87 + 2.74 86.51 + 21.92
**
 11.0 127.6 + 16.2
**
 16.2 46.09 + 20.49
$
 5.8 
Benzoic acids        
  4-hydroxybenzoic acid 0.82 + 0.33 4.40 + 1.13 5.3 3.60 + 1.13
*
 4.4 2.06 + 0.57 2.5 
  3,4-Dihydroxybenzoic acid 0.02 + 0.01 0.10 + 0.03 4.7 1.20 + 0.55
**&&
 56.9 0.04 + 0.02
$$
 2.0 
  Gluc-3-hydroxybenzoic acid 0.01 + 0.01 0.005 + 0.002 0.4 0.15 + 0.07
**&&
 10.6 0.003 + 0.002
$$
 0.3 
  Gluc-4-hydroxybenzoic acid n.d. 0.04 + 0.02
**
 > 31 0.02 + 0.005
*
 > 7 0.01 + 0.01 > 10 
  Sulf-3,4-dihydroxybenzoic acid 0.39 + 0.12 2.43 + 0.68 5.0 3.90 + 2.12
**
 5.1 1.82 + 0.72 3.8 
  Sulf-vanillic-acid 19.43 + 3.83 12.04 + 3.92 0.6 25.92 + 4.41 1.3 9.98 + 3.60
$
 0.5 
  Total 20.68 + 3.57 19.01 + 5.17 0.9 34.79 + 1.70 1.7 13.92 + 4.53 0.7 
Cinnamic acids        
  Caffeic acid 0.06 + 0.03 n.d.
*





  m-coumaric acid 6.92 + 3.26 0.37 + 0.12
*
 0.05 13.96 + 1.74
&&
 2.0 3.73 + 1.11
&&$$
 0.5 
  p-coumaric acid 1.43 + 0.53 0.16 + 0.04 0.1 1.86 + 0.53
&&
 1.3 0.10 + 0.04
$$
 0.07 
  Sulf-coumaric acid-1 n.d. 0.38 + 0.16
**
 > 38 0.79 + 0.27
**
 > 790 0.14 + 0.13
*
 > 14 
  Sulf-coumaric acid-2 0.002 + 0.001 0.35 + 0.15
**
 169.3 0.75 + 0.24
**
 375.0 0.08 + 0.08
$
 38.0 
  Ferulic acid 0.91 + 0.37 n.d.
**





  Total 9.31 + 3.90 1.26 + 0.33 0.1 18.68 + 2.00
&&
 2.0 4.05 + 1.27
&$$
 0.4 
Glycinated benzoic acids        
  Hippuric acid 2.85 + 1.05 167.85 + 73.30
**
 58.9 125.18 + 73.97 43.9 105.48 + 75.36 37.0 
  Hydroxyhippuric acid 0.02 + 0.02 0.22 + 0.07
*
 12.7 0.96 + 0.20
**&&
 48.0 0.12 + 0.06
$$
 7.2 
  Me-hippuric acid-1 0.01 + 0.01 0.33 + 0.13
**
 37.3 5.32 + 2.02
**
 532.0 0.13 + 0.12 14.3 
  Me-hippuric acid-2 0.17 + 0.07 n.d.
**





  Total   3.05 + 1.10 168.40 + 73.41
**
 55.3 132.25 + 74.10
*
 43.4 105.73 + 75.51 34.7 
Total of microbial-derived metabolites
3
 473.21 + 174.23 441.61 + 123.04 0.9 1375.03 + 534.83 2.9 355.49 + 164.69 0.7 
n.d., non-detected; Gluc, glucuronide; Me, methyl; Sulf, sulfated  
         
1
 Values generated by dividing  metabolite concentration  by the concentration of the same metabolite in the STD group. When the compound was n.d. in the STD group, the 





 Enterolactone  occurred in all groups at concentrations above the highest point in the calibration curve.. 
3 
Enterolactone was not included in the calculation of the total microbial metabolites because its actual concentration could not be determined. 
*
 P < 0.05 vs STD group. 
**
P< 0.01 vs STD group. 
&
 P < 0.05 vs HFHS group. 
&&
 P< 0.01 vs HFHS  group.  
$
 P < 0.05 vs STD + GSE group. 
$$
 P < 0.01 vs STD + GSE 




Table 3. Microbial-derived proanthocyanidin metabolites in faeces from rats fed a standard (STD) diet or a high-fat high-sucrose (HFHS) diet 
without or with grape seed extract (GSE). Results expressed as µmol/g dried faeces, after quantification with structurally similar  commercial 
standards (see Table S1). 
Metabolite STD HFHS STD + GSE HFHS + GSE 
 mean + s.e.m. mean + s.e.m. x-fold
1
 mean + s.e.m. x-fold
1
 mean + s.e.m. x-fold
1
 
Phenylvaleric acids           
  3-Hydroxyphenylvaleric acid  0.19 + 0.09 n.d.
**
 - 55.59 + 49.19
*&&
 292.6 27.44 + 22.72
*&&
 147.4 
Phenylpropionic acids         
  3-Hydroxyphenylpropionic acid 2.67 + 2.30 n.d.
**
 - 5.75 + 5.25
&&
 2.2 0.35 + 0.07
&&
 0.13 
  4-Hydroxyphenylpropionic acid 0.65 + 0.16 0.20 + 0.11 0.3 2.32 + 1.82 3.6 39.63 + 33.96
&&
 61.3 
  Total  3.32 + 2.47 0.20 + 0.11
*
 0.3 8.07 + 5.10
&&
 2.4 39.99 + 34.00
&
 12.0 
Benzoic acids         
  4-hydroxybenzoic acid n.d. n.d.
*
 - 0.06 + 0.04
*&
 > 615 n.d.
*$
 - 
  3,4-Dihydroxybenzoic acid n.d. n.d.  0.01 + 0.01
**&&
 > 9 n.d.
$$
 - 
  Total n.d. n.d. - 0.07 + 0.05
**&&
 > 48 n.d.
$$
 - 
Cinnamic acids         





  p-coumaric acid 0.002 + 0.001 0.001 + 0.0002 0.5 0.15 + 0.12
*&
 75.0 0.005 + 0.003 2.2 
  Total 0.003 + 0.0020 0.001 + 0.0002 0.3 0.18 + 0.14
*&&
 60.0 0.005 + 0.003
$
 2.2 
Glycinated benzoic acids         
  Hippuric acid 0.003 + 0.002 n.d. - 0.003 + 0.002 1.0 0.02 + 0.02 5.3 
  Me-hippuric acid-1 0.39 + 0.31 n.d.
**





  Me-hippuric acid-2 n.d. n.d.
**
 - 354.38 + 324.50
**&&
 > 1,000 n.d.
 $$
 - 
  Total   0.39 + 0.31 n.d. - 1046.95 + 970.73
**&&
 2664.0 0.02 + 0.02
*$$
 0.04 
Total of microbial-derived metabolites  3.90 + 2.49 0.20 + 0.11
*
 0.03 1110.86 + 1018.35
**&&
 284.8 67.46 + 56.73
&&
 17.3 
n.d., non-detected; Gluc, glucuronide; Me, methyl; Sulf, sulphated 
1
 Values generated by dividing metabolite concentration by the concentration of the same metabolite in the STD group . When the compound was n.d. in the STD group, the 
limit of detection  was used  to calculate the x-fold value. 
*
 P < 0.05 vs STD group. 
**
P< 0.01 vs STD group. 
&
 P < 0.05 vs HFHS group. 
&&
 P< 0.01 vs HFHS  group. 
$
 P < 0.05 vs STD + GSE group.  
$$
 P < 0.01 vs STD + GSE 




Table 4. (Epi)catechin and (epi)gallocatechin conjugated metabolites in urine from rats fed a standard (STD) diet or a high-fat high-sucrose 
(HFHS) diet without or with grape seed extract (GSE). Results expressed as µM, after quantification with structurally similar  commercial 
standard (seeTable S1). 
Metabolite STD HFHS STD + GSE HFHS+ GSE 
 mean + s.e.m. mean + s.e.m. x-fold
1
 mean + s.e.m. x-fold
1
 mean + s.e.m. x-fold
1
 
EC monoconjugated          
  Gluc-EC-1  n.d. n.d. - 0.32 + 0.16
**&&
 > 62 0.26 + 0.11
**&&
 > 52 
  Gluc-EC-2 n.d. n.d. - 0.22 + 0.11
*&
 > 43 0.32 + 0.17
*&
 > 64 
  Gluc-EC-3 0.04 + 0.02 0.20 + 0.06 5.4 0.17 + 0.06 4.3 0.24 + 0.13
*
 6.4 
  Gluc-EC-4 0.02 + 0.001 0.11 + 0.03 5.6 0.05 + 0.02 2.9 0.05 + 0.01
**
 2.8 
  Gluc-EC-5 0.05 + 0.03 0.69 + 0.29 13.2 0.11 + 0.06 2.2 0.55 + 0.26
**
 10.6 
  Total  0.11 + 0.04 1.00 + 0.38 9.2 0.88 + 0.35
*
 8.1 1.44 + 0.64
**
 19.8 
EC diconjugated         
  Gluc-Sulf-EC 0.07 + 0.02 0.02 + 0.01 0.3 0.19 + 0.09 2.8 0.03 + 0.01
&$$
 0.4 
  Me-Gluc-EC-1 n.d. n.d. - 0.05 + 0.02
**&&
 > 10 0.05 + 0.01
**&&
 > 10 
  Me-Gluc-EC-2 n.d. n.d. - 0.83 + 0.27
**&&
 > 167 1.67 + 0.52
**&&
 > 333 
  Me-Gluc-EC-3 n.d. n.d. - 0.30 + 0.10
**&&
 > 59 0.96 + 0.34
**&&
 > 190 
  Me-Sulf-EC 0.15 + 0.05 0.15 + 0.02 1.0 0.16 + 0.03 1.1 0.15 + 0.04 1.0 
  Total  0.20 + 0.07 0.17 + 0.07 0.8 1.55 + 0.46
**&&
 7.8 2.85 + 0.86
**&&
 14.2 
EC triconjugated         
  3Me-EC 0.06 + 0.02 0.09 + 0.03 1.4 0.06 + 0.02 1.0 0.06 + 0.01 1.0 
  2Me-Gluc-EC 0.05 + 0.01 0.06 + 0.02 1.6 0.09 + 0.02 1.8 0.03 + 0.01 0.6 
  Total  0.10 + 0.03 0.15 + 0.05 1.5 0.15 + 0.03 1.5 0.10 + 0.02 1.0 
EGC diconjugated         
  2Sulf-EGC 0.84 + 0.17 1.54 + 0.46 1.8 1.22 + 0.24 1.1 0.89 + 0.25 1.1 
EGC triconjugated         
  Me-Gluc-Sulf-EGC 0.23 + 0.07 0.13 + 0.13 0.5 0.46 + 0.06 2.0 0.26 + 0.10 1.1 
Total of conjugated metabolites  1.49 + 0.33 2.99 + 1.06 2.3 4.25 + 0.94 2.9 8.62 + 2.46
**&&$
 5.8 
n.d., non-detected; Gluc, glucuronide; Me, methyl; Sulf, sulphated 
1
 Values generated by dividing metabolite concentration by the concentration of the same metabolite in the STD group . When the compound was n.d. in the STD group, the 
limit of detection  was used  to calculate the x-fold value. 
*
 P < 0.05 vs STD group. 
**
P< 0.01 vs STD group. 
&
 P < 0.05 vs HFHS group. 
&&
 P< 0.01 vs HFHS group.
 $
 P < 0.05 vs STD + GSE group.  
$$
 P < 0.01 vs STD + GSE group. 
Comparisons were performed using the Kruskal-Wallis and Mann-Whitney U tests 
 
